Status:

UNKNOWN

Growth Hormone Treatment of Young Growth Hormone-Deficient Adults

Lead Sponsor:

University Hospital, Angers

Collaborating Sponsors:

Novo Nordisk A/S

Conditions:

Growth Hormone Deficiency

Eligibility:

All Genders

18-35 years

Brief Summary

Hypopituitary adults with all the hormonal deficiencies are well subsituted excepted for the growth hormone (GH) and died earlier than the rest of the population. GH deficiency involves a fat mass inc...

Eligibility Criteria

Inclusion

  • Adults (age \> 18-35 years)
  • Stable body mass +/- 5 kg in 3 months
  • GH deficiency since childhood, treated by GH during childhood, having stopped GH treatment at the end of adolescence
  • Want to receive again GH treatment or refusing new GH treatment
  • GH deficiency confirmed at adulthood by GHRH-Arginine test
  • Women receiving GH treatment must have a efficient contraceptive method
  • Have given a writing informed consent

Exclusion

  • Somatotropic insufficiency
  • All pathologies or treatment modifing energetic metabolism, excepted diabet mellitus and obesity
  • Participating to another clinical trial during the three months befor inclusion
  • Pathologies modifing bone metabolism
  • Pregnancy/Feeding
  • Refusal to consent

Key Trial Info

Start Date :

May 1 2005

Trial Type :

OBSERVATIONAL

End Date :

August 1 2005

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00187993

Start Date

May 1 2005

End Date

August 1 2005

Last Update

September 16 2005

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

UH of Angers

Angers, France, 49000

2

UH of Brest

Brest, France

3

UH of Caen

Caen, France

4

UH of Limoges

Limoges, France